A new analysis from The Washington Post shows that Americans are using GLP-1 drugs at unprecedented rates. Monthly prescriptions for medications like Ozempic, Mounjaro, and Wegovy have climbed to nearly 30 million, with a significant portion of the increase coming from patients who are new to these treatments.

Key takeaways

  • GLP-1 drug prescriptions in the U.S. have reached approximately 30 million per month, according to data from IQVIA analyzed by The Washington Post.
  • Nearly half of the new prescriptions written in 2024 went to patients who had not previously taken a GLP-1 drug, signaling a widening patient base.
  • Ozempic and Mounjaro together accounted for about half of all GLP-1 prescriptions in 2024.
  • Many new users are younger and starting on lower doses, which may reflect use for weight loss rather than diabetes.
  • Demand continues to outpace supply, with shortages of some brand-name and compounded versions still being reported.

Record prescription numbers

According to The Washington Post’s analysis of prescription data from IQVIA, the number of monthly GLP-1 prescriptions written in the United States has reached roughly 30 million. That represents a dramatic increase from just a few years ago, when these medications were used primarily by people with type 2 diabetes.

The analysis found that Ozempic and Mounjaro, both made by Novo Nordisk and Eli Lilly respectively, together made up about half of all GLP-1 prescriptions filled in 2024. Other popular drugs in this class include Wegovy, Zepbound, and Rybelsus.

Who is starting these drugs?

A notable finding from the report is that about 48 percent of new GLP-1 prescriptions issued in the first half of 2024 went to people who had never taken a drug in this class before. This suggests that the market is not merely shifting existing patients between different brand names but is actually bringing in a large wave of new users.

The Post’s analysis also indicated that a growing number of these new patients are younger and are starting on lower doses. This pattern is consistent with the drugs’ growing popularity for weight management, rather than strictly for diabetes. Wegovy and Zepbound, for instance, are specifically approved for chronic weight management in the U.S.

Supply and demand challenges

Despite the surge in manufacturing capacity, the report notes that shortages continue to affect the availability of some GLP-1 products. The Food and Drug Administration has periodically listed certain doses of Ozempic, Mounjaro, and Wegovy as in short supply, which has driven some patients to seek compounded versions of the drugs.

The high demand has also led to an increase in off-label prescribing. While the FDA has approved these medications for specific indications, some doctors are prescribing them for patients whose conditions may not exactly match the approved criteria, particularly for weight loss.

Implications for patients and the healthcare system

The rising prescription numbers reflect a shift in how GLP-1 drugs are perceived and used. Originally developed for type 2 diabetes, they are now widely sought after for weight loss. This has created new discussions about insurance coverage, out-of-pocket costs, and long-term health outcomes.

Public health experts quoted in the original report caution that while these drugs can be effective, they are not a substitute for healthy lifestyle changes. Patients considering GLP-1 therapies should discuss the potential benefits and risks with their healthcare provider and be aware of the financial costs, which can exceed $1,000 per month without insurance.

Frequently Asked Questions

What are GLP-1 drugs?

GLP-1 drugs, also known as glucagon-like peptide-1 receptor agonists, are a class of medications that help manage blood sugar levels and promote satiety. They are used to treat type 2 diabetes and, in some formulations, for chronic weight management. Popular brands include Ozempic, Mounjaro, Wegovy, and Zepbound.

Why are GLP-1 prescriptions rising so quickly?

The rapid increase is driven by growing awareness of their weight loss benefits, broader insurance coverage for weight management, and aggressive marketing by drug manufacturers. The Washington Post report indicates that nearly half of new prescriptions are going to first-time users, many of whom are seeking help with weight loss rather than diabetes control.

Are GLP-1 drugs safe for weight loss?

When used under medical supervision and as approved by the FDA, GLP-1 drugs are considered safe for weight loss. However, they can cause side effects such as nausea, vomiting, and diarrhea. Long-term studies are still ongoing, and experts recommend that patients use these medications as part of a comprehensive plan that includes diet and exercise.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.